The guidelines address the following opportunistic infections: PCP, Toxo, Cryptosporidia, Microsporidia, TB, MAC, Bacterial Respiratory Disease, Bacterial Enteric Disease, Bartonella, Syphilis, Candida, Endemic Mycoses (Cryptococcosis, Histo, Cocci, Aspergillus) CMV, Non-CMV Herpes (HSV, VZV, HHV-8) HPV, HBV, HCV, PML/JCV, and Geographic OIs of Specific Consideration (Malaria, Penicilliosis, Leishmania, Chagas, Isospora).
Recommendations in this report cover:
- Preventing exposure to opportunistic pathogens
- Preventing disease
- Discontinuing primary prophylaxis after immune reconstitution
- Treating disease
- When to start ART in the setting of an acute OI
- Monitoring for adverse effects (including immune reconstitution inflammatory syndrome [IRIS])
- Managing treatment failure
- Preventing disease recurrence ("secondary prophylaxis" or chronic maintenance therapy)
- Discontinuing secondary prophylaxis after immune reconstitution
- Special considerations during pregnancy
Slide sets to accompany the guidelines are available from the National Coordinating Resource Center.
Add comment